Women with axial spondyloarthritis (axSpA) or other inflammatory diseases maintained stable therapeutic levels of Cimzia (certolizumab pegol) throughout pregnancy,…
Articles by Andrea Lobo
AVT05, Alvotech’s biosimilar candidate to treat ankylosing spondylitis (AS) and other chronic inflammatory diseases, showed a similar pharmacological…
A year of treatment with bimekizumab was safe and significantly eased symptoms of axial spondyloarthritis (axSpA) in participants…
Long-term use of Cimzia (certolizumab pegol) is associated with a higher clinical response to treatment and lower disease activity…
A blood test for bone disease that measures the levels of an enzyme called alkaline phosphatase (ALP) may predict disease…
The U.S. Food and Drug Administration (FDA) has approved Yuflyma (adalimumab-aaty), a high concentration biosimilar of Humira (adalimumab),…
Proteins associated with inflammation and immune system function were identified as potential blood biomarkers for the diagnosis and monitoring of…
AVT02, a high-concentration and low-volume biosimilar to AbbVie’s Humira (adalimumab), was approved by health regulators in Australia to…
Early initiation of anti-tumor necrosis factor (TNF) medications may be associated with an increased risk of cardiovascular events in…